Volpara and Lunit co-host a session on interval cancer reduction using artificial intelligence
MONTREAL, April 11, 2024 /PRNewswire/ — Volpara Health Technologies Ltd. (ASX: VHT), a global leader in cancer early detection and prevention software, today unveiled a new central, digital destination for managing mammography systems, staff credentials and professional development to support compliance with the Food Administration’s Mammography Quality Standards Act (MQSA) and medicines. Volpara® Quiver™ software was presented at the Society for Breast Imaging (SBI) Annual Symposium along with the company’s suite of solutions for breast density assessment, mammography quality and cancer risk assessment.
“Breast imaging has long been at the forefront of technology adoption. And yet, when it comes to demonstrating MQSA compliance—which has a big stake—mammography centers rely on reams of binders and manual, repetitive and tedious processes,” he says. Terry Thomas, director of Volpar. “We lovingly refer to Quiver as our ‘Binder Reduction Act’ or BRA. By leveraging our user-loved Volpara Analytics platform for automated EQUIP reports and image selection for ACR accreditation, we are able to deliver a more complete Quiver digital compliance experience that can accelerate your preparation for audit and give you peace of mind and shelf space.”
Quiver helps quality assurance managers ensure everything is in order long before inspection day. Quiver placement is automatically populated by clinic, mammography system, and technologist activity from Volpara® Analytics™ software. The software can be accessed from any web-browser and allows clinic-by-clinic insight into technologists’ continuous education records and mammography system quality assurance documentation. Techs can upload their own records, and email notifications can alert staff when their credits are about to expire. Free credits are also available through Volpara® Hive™, an online community exclusively for Volpara users. All documentation can be presented to inspectors digitally or printed.
Reducing cancer intervals with AI and personalized screening
Volpara previously announced that it had entered into an Agreement on the implementation of the scheme with Lunit®. At SBI, the companies are co-hosting a Learning Lab session titled “Interval Cancer Reduction with Artificial Intelligence and Personalized Screening.” on April 11 14:45 – 15:45 in room 513D. dr. Manisha Bhal from Mass General Hospital and Dr. Stamatia Destounis of Elizabeth Wende Breast Care will share her experience with Lunit’s INSIGHT™ AI software for early cancer detection and Volpara’s Risk Pathways and Scorecard software.
To see a demo of Quiver and Volpara’s other latest software developments for breast centers, visit booth #118 at SBI 2024.
About Volpara Health (ASX: VHT)
Volpara Health makes software to save families from cancer. Health care providers use Volpara to better understand cancer risk, empower patients to make personal care decisions, and make recommendations about additional imaging, genetic testing, and other interventions. Our AI image analysis enables radiologists to precisely quantify breast tissue and helps technologists create mammograms with optimal image quality, positioning, compression and dose. In an industry facing increasing staff shortages, our software streamlines operations, compliance preparation and provides key performance insights that support continuous quality improvement.
Volpara is a preferred partner of leading healthcare institutions worldwide. Our software is used by more than 5,600 technologists in more than 2,000 facilities, impacting nearly 17 million patients worldwide. It helps providers conduct more than three million cancer risk assessments each year and can be used standalone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware and genetic laboratories. Volpara holds the most stringent safety certifications and numerous patents and regulatory registrations, including FDA approval and CE marking. Since listing on the ASX in April 2016Society raised 132 million Australian dollars. With an office in SeattleVolpara is based in WellingtonNew Zealand.
For more information, visit www.volparahealth.com.
SOURCE Volpara Health, Inc.
